Jane Street Group LLC Has $45,000 Holdings in Ovid Therapeutics Inc. (NASDAQ:OVID)

Jane Street Group LLC trimmed its holdings in shares of Ovid Therapeutics Inc. (NASDAQ:OVID) by 61.1% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 38,399 shares of the company’s stock after selling 60,191 shares during the period. Jane Street Group LLC owned about 0.05% of Ovid Therapeutics worth $45,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of OVID. DCF Advisers LLC raised its holdings in Ovid Therapeutics by 111.6% in the 2nd quarter. DCF Advisers LLC now owns 41,750 shares of the company’s stock valued at $32,000 after acquiring an additional 22,020 shares during the period. FMR LLC lifted its holdings in shares of Ovid Therapeutics by 1,907.4% during the third quarter. FMR LLC now owns 50,225 shares of the company’s stock worth $59,000 after purchasing an additional 47,723 shares during the period. Verition Fund Management LLC acquired a new position in shares of Ovid Therapeutics during the third quarter worth $88,000. Assenagon Asset Management S.A. bought a new position in Ovid Therapeutics during the third quarter worth $102,000. Finally, GSA Capital Partners LLP increased its stake in Ovid Therapeutics by 118.0% in the third quarter. GSA Capital Partners LLP now owns 260,509 shares of the company’s stock valued at $307,000 after purchasing an additional 141,002 shares in the last quarter. 72.24% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Separately, HC Wainwright reiterated a “buy” rating and set a $3.00 price objective on shares of Ovid Therapeutics in a report on Wednesday, December 4th. Two analysts have rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Ovid Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $4.04.

Ovid Therapeutics Price Performance

Shares of Ovid Therapeutics stock opened at $0.76 on Thursday. Ovid Therapeutics Inc. has a 52-week low of $0.68 and a 52-week high of $4.10. The stock has a market capitalization of $54.10 million, a price-to-earnings ratio of -1.62 and a beta of 0.34. The company has a fifty day moving average of $1.05 and a 200-day moving average of $1.07. The company has a debt-to-equity ratio of 0.18, a quick ratio of 5.66 and a current ratio of 5.66.

Ovid Therapeutics (NASDAQ:OVID) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.01). Ovid Therapeutics had a negative return on equity of 39.24% and a negative net margin of 5,142.56%. The company had revenue of $0.17 million during the quarter, compared to the consensus estimate of $0.15 million. Equities research analysts expect that Ovid Therapeutics Inc. will post -0.48 EPS for the current year.

Ovid Therapeutics Profile

Ovid Therapeutics Inc, a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies.